1. Home
  2. BEAM vs EVCM Comparison

BEAM vs EVCM Comparison

Compare BEAM & EVCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • EVCM
  • Stock Information
  • Founded
  • BEAM 2017
  • EVCM 2006
  • Country
  • BEAM United States
  • EVCM United States
  • Employees
  • BEAM N/A
  • EVCM N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • EVCM EDP Services
  • Sector
  • BEAM Health Care
  • EVCM Technology
  • Exchange
  • BEAM Nasdaq
  • EVCM Nasdaq
  • Market Cap
  • BEAM 1.6B
  • EVCM 1.7B
  • IPO Year
  • BEAM 2020
  • EVCM 2021
  • Fundamental
  • Price
  • BEAM $19.88
  • EVCM $10.67
  • Analyst Decision
  • BEAM Strong Buy
  • EVCM Buy
  • Analyst Count
  • BEAM 11
  • EVCM 12
  • Target Price
  • BEAM $48.90
  • EVCM $11.67
  • AVG Volume (30 Days)
  • BEAM 2.0M
  • EVCM 255.8K
  • Earning Date
  • BEAM 08-05-2025
  • EVCM 08-05-2025
  • Dividend Yield
  • BEAM N/A
  • EVCM N/A
  • EPS Growth
  • BEAM N/A
  • EVCM N/A
  • EPS
  • BEAM N/A
  • EVCM N/A
  • Revenue
  • BEAM $63,578,000.00
  • EVCM $703,186,000.00
  • Revenue This Year
  • BEAM N/A
  • EVCM N/A
  • Revenue Next Year
  • BEAM $8.82
  • EVCM $6.31
  • P/E Ratio
  • BEAM N/A
  • EVCM N/A
  • Revenue Growth
  • BEAM N/A
  • EVCM 7.84
  • 52 Week Low
  • BEAM $13.53
  • EVCM $8.10
  • 52 Week High
  • BEAM $35.25
  • EVCM $12.35
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 67.72
  • EVCM 62.56
  • Support Level
  • BEAM $16.59
  • EVCM $9.47
  • Resistance Level
  • BEAM $17.38
  • EVCM $9.82
  • Average True Range (ATR)
  • BEAM 1.09
  • EVCM 0.29
  • MACD
  • BEAM 0.24
  • EVCM 0.10
  • Stochastic Oscillator
  • BEAM 93.78
  • EVCM 99.22

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About EVCM EverCommerce Inc.

EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is primarily generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.

Share on Social Networks: